logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
19/09/2025
Federal Reserve's Kashkari: the upcoming interest rate cut is a kind of insurance to maintain stability in the job market.
Latest
2 m ago
Qidi New Materials: Received designated and small batch orders for carbon fiber shells of humanoid robots from a leading domestic host factory.
2 m ago
Spot silver rose by 1.5% intraday, reaching $42.42 per ounce.
2 m ago
US stocks surge | Pony.ai (PONY.US) increases by over 4%, CFO says key profitability goal will be achieved in early 2026
3 m ago
WTI crude oil futures fell by 0.4% to $62.60. The Japanese ETF listed in the US fell by 0.77% to $80.86, dropping by over 1.1% at the start of trading.
3 m ago
In early trading on Friday, the Dow component Johnson & Johnson rose 1%. Recently, Johnson & Johnson announced that it has submitted an application to the European Medicines Agency seeking approval for the marketing of Icotrokinra, an investigational once-daily oral peptide therapy developed in collaboration with Protagonist. It is intended for the treatment of adults and pediatric patients aged 12 and above with moderate to severe plaque psoriasis. The experimental psoriasis drug is said to show potential superiority over AbbVie's therapy.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.